AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27655115 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based structured exercise (sitting Tai Chi)
Number of subjects: 272
Study 27655115 — intervention group
Group type: COMPARATOR
Intervention: Social contact control
Number of subjects: 272
Study 27655184 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid Facebook advertisements
Number of subjects: 115
Study 27655184 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment approaches
Number of subjects: 115
Study 27655260 — intervention group
Group type: EXPERIMENTAL
Intervention: History of falls in the 6 months prior to surgery
Number of subjects: 0
Study 27655442 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal plasma betaine
Number of subjects: 955
Study 27655463 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleepers (≥ 8 h)
Number of subjects: 500
Study 27655463 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleepers (6-8 h)
Number of subjects: 500
Study 27655463 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleepers (< 6 h)
Number of subjects: 500
Study 27656000 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LVEF by ≥5 U (improvement)
Number of subjects: 2484
Study 27656000 — intervention group
Group type: COMPARATOR
Intervention: Change in LVEF
Number of subjects: 2484
Study 27656788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg, administered over 100min) during acute-phase treatment (up to 6 thrice-weekly infusions)
Number of subjects: 12
Study 27656788 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase treatment with 4 weekly ketamine infusions
Number of subjects: 12
Study 27656788 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-continuation phase follow-up (4 weeks, no further ketamine infusions)
Number of subjects: 12
Study 27656788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute-phase and continuation-phase treatment
Number of subjects: 12
Study 27656840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet for 12 months
Number of subjects: 7
Study 27657052 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with mild to moderate COPD (GOLD stages 1 and 2)
Number of subjects: 0
Study 27657052 — intervention group
Group type: COMPARATOR
Intervention: Healthy smokers
Number of subjects: 0
Study 27657052 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 0
Study 27657052 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 0
Study 27657348 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (Rotarix™)
Number of subjects: 596
Study 27657348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 27657493 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with liver-specific contrast
Number of subjects: 407
Study 27657493 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 407
Study 27657493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HCC
Number of subjects: 407
Study 27657681 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat treatment
Number of subjects: 51
Study 27657899 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation
Number of subjects: 18
Study 27657899 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 18
Study 27658437 — intervention group
Group type: COMPARATOR
Intervention: miR-150-5p
Number of subjects: 41
Study 27658437 — intervention group
Group type: COMPARATOR
Intervention: miR-146b-5p
Number of subjects: 41
Study 27658437 — intervention group
Group type: COMPARATOR
Intervention: miR-1
Number of subjects: 41
Study 27658437 — intervention group
Group type: COMPARATOR
Intervention: Logistic model with 3 microRNAs
Number of subjects: 41
Study 27658471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT) via duodenal route (44.4%), colonic (41.1%), capsule (9.8%), gastric (3.0%)
Number of subjects: 133
Study 27658581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg
Number of subjects: 30
Study 27658581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27658740 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg daily for 12 weeks
Number of subjects: 17
Study 27658757 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than normal range of BUN/creatinine ratio
Number of subjects: 2033
Study 27658863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x (12 mg/mL) and rhuGM-CSF (0.6 mg/mL) administered intradermally over 12 weeks followed by romidepsin (5 mg/m2) intravenously once a week for 3 weeks.
Number of subjects: 20
Study 27658863 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin treatment (5 mg/m2) administered intravenously once a week for 3 weeks.
Number of subjects: 20
Study 27658863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x and rhuGM-CSF followed by romidepsin treatment.
Number of subjects: 20
Study 27658864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg long-acting rilpivirine
Number of subjects: 36
Study 27658864 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg long-acting rilpivirine
Number of subjects: 36
Study 27658864 — intervention group
Group type: EXPERIMENTAL
Intervention: long-acting rilpivirine
Number of subjects: 36
Study 27658870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) taken as one tablet per day for a median of 72 weeks
Number of subjects: 1224
Study 27658906 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE) features
Number of subjects: 25
Study 27658906 — intervention group
Group type: EXPERIMENTAL
Intervention: VLE neoplasia prediction score
Number of subjects: 25
Study 27658980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute leukoencephalopathy during chemotherapy treatment
Number of subjects: 190
Study 27659464 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 927
Study 27659464 — intervention group
Group type: EXPERIMENTAL
Intervention: First NGAL
Number of subjects: 927
Study 27659464 — intervention group
Group type: EXPERIMENTAL
Intervention: First NGAL <150 ng/ml
Number of subjects: 927
Study 27659897 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation based on a protocol (formal Telephone Medical Advice - fTMA)
Number of subjects: 2880
Study 27659897 — intervention group
Group type: COMPARATOR
Intervention: Usual handling of calls by call centre physician
Number of subjects: 2880
Study 27660108 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) detected in CMR
Number of subjects: 20
Study 27660125 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise commenced in early pregnancy
Number of subjects: 0
Study 27660125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study 27660316 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Preventive (digital preventive tool)
Number of subjects: 185
Study 27660316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 185
Study 27660322 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Comparison (PC)
Number of subjects: 234
Study 27660322 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable Justifications (JA)
Number of subjects: 234
Study 27660322 — intervention group
Group type: COMPARATOR
Intervention: Suggested Alternatives (SA)
Number of subjects: 234
Study 27660322 — intervention group
Group type: COMPARATOR
Intervention: Pay-for-performance
Number of subjects: 234
Study 27660322 — intervention group
Group type: COMPARATOR
Intervention: Additional clinic time
Number of subjects: 234
Study 27660515 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with <10 pack-years of smoking history
Number of subjects: 203
Study 27660515 — intervention group
Group type: COMPARATOR
Intervention: Patients with ≥10 pack-years of smoking history
Number of subjects: 203
Study 27660663 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily insulin lispro low mixture (LM25)
Number of subjects: 162
Study 27660663 — intervention group
Group type: COMPARATOR
Intervention: Once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL)
Number of subjects: 162
Study 27661411 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients
Number of subjects: 22
Study 27661411 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 22
Study 27662790 — intervention group
Group type: EXPERIMENTAL
Intervention: Good movement quality group (n=19)
Number of subjects: 59
Study 27662790 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate movement quality group (n=20)
Number of subjects: 59
Study 27662790 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor movement quality group (n=20)
Number of subjects: 59
Study 27662790 — intervention group
Group type: COMPARATOR
Intervention: Comparison between good and poor movement quality groups
Number of subjects: 59
Study 27662790 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ankle dorsiflexion ROM and Lateral Step Down Test scores
Number of subjects: 59
Study 27663201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID plus background methotrexate (ORAL Scan)
Number of subjects: 1600
Study 27663201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID as monotherapy (ORAL Start)
Number of subjects: 1600
Study 27663201 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1600
Study 27663508 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Computer-Assisted Client Assessment Survey (iCCAS)
Number of subjects: 74
Study 27663515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus radiotherapy
Number of subjects: 1
Study 27663759 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate + HSRT (3 × 9 Gy)
Number of subjects: 30
Study 27663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Training interventions after first training
Number of subjects: 22
Study 27663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Training interventions after further training
Number of subjects: 22
Study 27664062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300 (insulin glargine 300 U/mL)
Number of subjects: 40
Study 27664171 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained non-nursing staff
Number of subjects: 0
Study 27664171 — intervention group
Group type: COMPARATOR
Intervention: Certified Nursing Assistants (CNAs)
Number of subjects: 0
Study 27664804 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 50
Study 27664804 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of glycine and kynurenine alone or in combination
Number of subjects: 50
Study 27664804 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 27666002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment with ticagrelor (at least 1.5h before PCI)
Number of subjects: 143
Study 27666002 — intervention group
Group type: COMPARATOR
Intervention: Control Group (ticagrelor administered immediately before PCI)
Number of subjects: 143
Study 27667713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs-TnT) measured at 48 hours after return of spontaneous circulation (ROSC)
Number of subjects: 699
Study 27667713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs-TnT) in patients with STEMI at 48 hours after ROSC
Number of subjects: 699
Study 27667713 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 33°C
Number of subjects: 699
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus/enterovirus
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Parainfluenza
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronavirus
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Human metapneumovirus
Number of subjects: 6266
Study 27667752 — intervention group
Group type: EXPERIMENTAL
Intervention: Human bocavirus (HBov)
Number of subjects: 6266
Study 27668024 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent NAC tablets
Number of subjects: 30
Study 27668024 — intervention group
Group type: COMPARATOR
Intervention: Oral solution NAC
Number of subjects: 30
Study 27668024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study 27669017 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (IIV-HD)
Number of subjects: 32000
Study 27669017 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose inactivated influenza vaccine (SD)
Number of subjects: 32000
Study 27669027 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic associations with emphysema distribution
Number of subjects: 11532
Study 27669027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene set analysis and in silico functional evaluation
Number of subjects: 11532
Study 27669153 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-month individualized resistance training intervention
Number of subjects: 37
Study 27669153 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-frail, maternal BMI ≤ 26.3 kg/m2)
Number of subjects: 37
Study 27669747 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG target ≤5.6 mmol/L
Number of subjects: 934
Study 27669747 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG target ≤6.1 mmol/L
Number of subjects: 934
Study 27669747 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG target ≤7.0 mmol/L
Number of subjects: 934
Study 27670515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (salt reduction education); duration: 3.5 months.
Number of subjects: 832
Study 27670515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention); duration: 3.5 months.
Number of subjects: 832
Study 27670519 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Couples Therapy (BCT) involving the gambler and the CSO
Number of subjects: 120
Study 27670519 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioural Therapy (CBT) involving the gambler alone
Number of subjects: 120
Study 27671037 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based formulary which eliminates copayment for high-value preventive medications
Number of subjects: 4714
Study 27671037 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management support program promoting health behavior change and medication adherence
Number of subjects: 4714
Study 27671037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of value-based formulary and self-management support program
Number of subjects: 4714
Study 27671037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4714
Study 27671742 — intervention group
Group type: EXPERIMENTAL
Intervention: EMOTION Coping Kids Managing Anxiety and Depression (EMOTION)
Number of subjects: 36
Study 27671742 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 36
Study 27671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with high vascular risk (37.2%)
Number of subjects: 2909
Study 27671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with medium vascular risk (15.1%)
Number of subjects: 2909
Study 27671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with low vascular risk (6.5%)
Number of subjects: 2909
Study 27671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins prescribed in patients with established cardiovascular disease (CVD) (75.3%)
Number of subjects: 2909
Study 27671901 — intervention group
Group type: COMPARATOR
Intervention: Increasing vascular risk and CVD
Number of subjects: 2909
Study 27672408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel after cryosurgery
Number of subjects: 16
Study 27672408 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery alone
Number of subjects: 16
Study 27672413 — intervention group
Group type: EXPERIMENTAL
Intervention: SB204 1%
Number of subjects: 153
Study 27672413 — intervention group
Group type: EXPERIMENTAL
Intervention: SB204 4%
Number of subjects: 153
Study 27672413 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 153
Study 27672413 — intervention group
Group type: EXPERIMENTAL
Intervention: SB204 1% and SB204 4%
Number of subjects: 153
Study 27672453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy
Number of subjects: 15
Study 27673310 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blind peer review
Number of subjects: 0
Study 27673310 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind peer review
Number of subjects: 0
Study 27673576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid profiling using gas chromatography (GC) method on whole seminal fluid sample.
Number of subjects: 155
Study 27673576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid profiling in seminal plasma and spermatozoa.
Number of subjects: 155
Study 27673576 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of fatty acids with sperm motility.
Number of subjects: 155
Study 27676257 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine-tenofovir disoproxil fumarate PrEP administered through daily directly observed therapy (DOT) for ten consecutive days.
Number of subjects: 50
Study 27676466 — intervention group
Group type: EXPERIMENTAL
Intervention: Average HbA1c exposure of 7.0 ± 1.1% (53 ± 11.6 mmol/mol)
Number of subjects: 879
Study 27676466 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for age, sex, race, education, smoking status, alcohol intake, knee pain, physical fitness, body mass index, diabetes mellitus medication and statin use, ancillary year visit, and study arm and site
Number of subjects: 879
Study 27676466 — intervention group
Group type: EXPERIMENTAL
Intervention: Further adjustment for prevalent diabetes mellitus-related comorbidities
Number of subjects: 879
Study 27676466 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification according to participant baseline age (<60 vs ≥ 60)
Number of subjects: 879
Study 27677166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum albumin (per 0.5 g/dl decrease)
Number of subjects: 913
Study 27677166 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AST (per doubling)
Number of subjects: 913
Study 27677166 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 913
Study 27677442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern with higher consumption of fruit gum, fruit juice, and potato dumpling; avoiding fruits and vegetables.
Number of subjects: 348
Study 27677442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower consumption frequencies of butter, cream cake, French fries, or high-percentage alcoholic beverages.
Number of subjects: 348
Study 27677481 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus Bortezomib and Dexamethasone
Number of subjects: 0
Study 27677481 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bortezomib and Dexamethasone
Number of subjects: 0
Study 27677503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213
Study 27677503 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 7213
Study 27677861 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RSBI (diaphragmatic-RSBI)
Number of subjects: 51
Study 27677861 — intervention group
Group type: EXPERIMENTAL
Intervention: RSBI (traditional RSBI)
Number of subjects: 51
Study 27677861 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning attempt
Number of subjects: 51
Study 27677861 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning failure details
Number of subjects: 51
Study 27678169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mission Reconnect (MR) program alone
Number of subjects: 160
Study 27678169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mission Reconnect (MR) plus the Prevention and Relationship Enhancement Program (PREP) for Strong Bonds weekend program
Number of subjects: 160
Study 27678169 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP alone
Number of subjects: 160
Study 27678169 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 160
Study 27678169 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner massage
Number of subjects: 160
Study 27678432 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg or 10 mg, increased to up to 80 mg based on LDL-C levels)
Number of subjects: 272
Study 27678432 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 272
Study 27678530 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 15242
Study 27678530 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 15242
Study 27678530 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 15242
Study 27678530 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 15242
Study 27678541 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP) 0.4 mg/kg
Number of subjects: 290
Study 27678541 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP) 0.8 mg/kg
Number of subjects: 290
Study 27678541 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant alkaline phosphatase (recAP) 1.6 mg/kg
Number of subjects: 290
Study 27678541 — intervention group
Group type: EXPERIMENTAL
Intervention: Most efficacious dose of recAP (to be determined in Part 2)
Number of subjects: 290
Study 27678541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290